US 10428157
Dosing regimens for use with PCSK9 inhibitors
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 10428157 (Dosing regimens for use with PCSK9 inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61P, A61P3/06